Home / Pharmaceuticals / Glioblastoma Multiforme Market By Drug Type (Bevacizumab, Temozolomide, Carmustine) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Glioblastoma Multiforme Market By Drug Type (Bevacizumab, Temozolomide, Carmustine) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: Jun 2016 | Report Code: 57903-06-16

This report on global glioblastoma multiforme market studies various drugs used for treatment of glioblastoma along with pipeline analysis of upcoming potential drugs.  Glioblastoma multiforme is the most common and most aggressive cancer that begins within the brain. According to Brain Tumour Foundation of Canada, The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours.

For the purpose of this study, the various drugs studied include bevacizumab, temozolomide, and carmustine. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for glioblastoma multiforme market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are TRC-105, VB-111, TOCA 511, DCVax-Brain, Rindopepimut (CDX-110), and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global glioblastoma multiforme market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Glioblastoma Multiforme Market

 


 

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Glioblastoma Multiforme Market Portaiture
2.2 Global Glioblastoma Multiforme Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Glioblastoma Multiforme Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Glioblastoma Multiforme Market: Market Dynamics and Outlook
3.1 Glioblastoma Multiforme Market Overview
3.2 Glioblastoma Multiforme Disease Overview and Treatments
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Glioblastoma Multiforme Market, 2015 (Value %)

Chapter 4 GlobalGlioblastoma Multiforme Market, By Type of Drug
4.1 Preface
4.2 Bevacizumab
4.3 Temozolomide
4.4 Carmustine
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 TRC-105
4.6.1.2 VB-111
4.6.1.3 TOCA 511
4.6.1.4 DCVax-Brain
4.6.1.5 Rindopepimut (CDX-110)
4.6.1.6 ICT-107
4.6.1.7 Others
4.6.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Glioblastoma Multiforme Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 AbbVie, Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Activartis GmbH
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Agenus Inc.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Arog Pharmaceuticals, Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Bristol-Myers Squibb Company
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Cavion LLC
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Celldex Therapeutics, Inc .
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Cortice Biosciences Inc.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Eisai Co., Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 F. Hoffmann-La Roche Ltd.
6.11.1 Business Description
6.11.2 Financial Health and Budget Allocation
6.11.3 Product Portfolio
6.11.4 News Coverage
6.12 Exelixis Inc.
6.12.1 Business Description
6.12.2 Financial Health and Budget Allocation
6.12.3 Product Portfolio
6.12.4 News Coverage
6.13 Peregrine Pharmaceuticals, Inc.
6.12.1 Business Description
6.12.2 Financial Health and Budget Allocation
6.12.3 Product Portfolio
6.12.4 News Coverage

List of Figures

FIG. 1 Global Glioblastoma Multiforme Market, by Type of Drugs, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Glioblastoma Multiforme Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Glioblastoma Multiforme Market, 2015
FIG. 4 Market Share Analysis: Global Glioblastoma Multiforme Market, 2015 (Value %)
FIG. 5 Global Bevacizumab Market, 2013 – 2022 (USD Mn)
FIG. 6 Global Temozolomide Market, 20137– 2022 (USD Mn)
FIG. 7 Global Carmustine Market, 2013 –2022 (USD Mn)
FIG. 8 Pipeline Analysis: Global TRC-105 Market, Upto 2022 (USD Mn)
FIG. 9 Pipeline Analysis: Global VB-111 Market, Upto 2022 (USD Mn)
FIG. 10 Pipeline Analysis: Global TOCA 511 Market, Upto 2022 (USD Mn)
FIG. 11 Pipeline Analysis: Global DCVax-Brain Market , Upto 2022 (USD Mn)
FIG. 12 Pipeline Analysis: Global Rindopepimut (CDX-110) Market, Upto 2022 (USD Mn)
FIG. 13 Pipeline Analysis: Global ICT-107 Market, Upto 2022 (USD Mn)
FIG. 14 Pipeline Analysis: Global Trivax (AV00113) Market, Upto 2022 (USD Mn)
FIG. 15 U.S.Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 16 Canada Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 17 U.K Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 18 Germany Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 19 Rest of Europe Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 20 China Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 21 Japan Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 22 Rest of Asia Pacific Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 23 Brazil Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 24 Mexico Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 25 Rest of the Latin America Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)
FIG. 26 Middle East and Africa Glioblastoma Multiforme Market, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Glioblastoma Multiforme Market, by Type of Drugs, 2013 – 2022 (USD Mn)
TABLE 2 Global Glioblastoma Multiforme Market, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia – Pacific Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Latin America Glioblastoma Multiforme Market, by Country, 2013 – 2022 (USD Mn)

According to American Association of Neurological Surgeons (AANS), The National Cancer Institute estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that in 2015, 15,320 of these diagnoses resulted in death. Glioblastoma multiforme (GBM) has an incidence of two to three per 100,000 adults per year, and accounts for 52% of all primary brain tumors. Overall, GBM accounts for about 17% of all tumors of the brain (primary and metastatic). It is categorized as one of the orphan diseases with high mortality rate.

Based on the type of drugs, the glioblastoma multiforme market is segmented into:

  • Temozolomide
  • Bevacizumab
  • Carmustine

Glioblastoma Multiforme Market

In base year 2015, temozolomide accounted for the largest market share of the global glioblastoma multiforme market. The key advantages possessed by temozolomide are delayed progression without impacting the quality of life and less adverse effects compared to other molecules. Medical practitioners suggest that, combination radiotherapy and temozolomide chemotherapy is currently the standard of care for most patients suffering from GBM. Temozolomide belongs to the class of alkylating agents; the mechanism of action comprises cell destruction initiated by abnormal methylations of DNA bases, and in particular the formation of O6-alkylguanine in DNA. The DNA repair enzyme -methylguanine-DNA methyltransferase (MGMT) antagonizes the genotoxic effects of alkylating agents and MGMT gene silencing through promoter methylation is a favorable prognostic marker, predicting benefits from this sort of chemotherapy in GBM. Thus, temozolomide is the first line therapy used for GBM treatment but ongoing research to enhance efficiency of bevacizumab in GBM treatment might affect the temozolomide market share in the near future.

For the purpose of this study, the global glioblastoma multiforme market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa

Glioblastoma Multiforme Market

In base year 2015, North America and Europe dominated the market with around 60% of the overall market share. The key factors assisting the growth of glioblastoma multiforme market in these regions are mounting support from government and non-government organizations to increase public awareness related to diagnosis and treatment of GBM and advanced healthcare infrastructure to boost the pipeline research in this market. Market experts suggest that, key GBM treatment drugs are initially approved in these regions as North American and European markets are the most lucrative pharmaceutical markets. The upcoming pipeline drugs are expected to play crucial role in the GBM market where early market entry and high drug prices would be the key factors that will boost the overall GBM market in North America and Europe initially. Asia-Pacific is expected to grow at a significant pace where Japan is observed as the leading market followed by China and India. India and China have a large low- and middle-income population; hence, demand for low cost treatments is high. However, in case of life threatening diseases such as GBM the scenario is different as the available treatments are limited and require higher cost.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients